Summary of "Video Clase de Uso racional de medicamentos"

Main ideas, concepts, and lessons

1) Purpose of “rational therapeutics”

The class introduces rational use of medications as a set of concepts and tools to:

Understand proper drug use comprehensively
Use medicines as a health tool
Avoid iatrogenic harm (harm caused by medical treatment)

2) What “rational use of medications” means (core definition)

Patients should receive medication in the real context where they are.

Medication use should not exceed what they need in:

Quantity
Duration / time

Because resources are limited, cost must be considered alongside clinical factors.

Using the WHO framing, the intended outcomes include:

Optimal / best effect
Minimum necessary number of medicines
Minimum adverse reactions and interactions
Less patient exposure overall
Preferably lower cost, but with priorities:
1. Effectiveness
2. Safety

3) Key variables to review before and during treatment

Review and decide based on:

Needs (whether medication is truly indicated)
Dosage
Treatment duration
Costs (cost is a final variable, but important)

4) Medicines are a “social good,” not a consumer commodity

The class contrasts two views:

Medicines treated like consumer goods → leads to overuse and misuse
Medicines as a social good → essential for health, requiring responsible rational use

Future healthcare professionals (nurses, pharmacists, doctors) must collaborate with:

Patients and caregivers
To build a “virtuous cycle” of appropriate medication use

5) Prevention and stepwise care over easy pharmacological answers

Medication should not replace prevention and lifestyle measures.

Example: For obesity and related conditions (e.g., hypertension, diabetes), walking/exercise may be more effective/healthy/natural than immediately starting pharmacological treatment.

The class criticizes:

Overmedicating populations because it’s the easiest/quickest answer
Skipping non-drug options (i.e., “no plan B” is not assumed)

Consequences of irrational drug use:

Too many drugs → more interactions
Adverse reactions
Higher costs
Unnecessary increases in healthcare resource use
Damage to patient trust, especially if harm leads to disability

6) How irrational use happens: market dynamics and system-level problems

Medicines are described as a major business, with strong pharmaceutical industry influence.

Examples/claims mentioned include:

Graph of Argentine pharmaceutical market growth (2019–2022) showing consumption and cost rising
Emergency rooms frequently seeing misuse, particularly misuse of insulin
A driver highlighted: insufficient patient training for proper use

Industry influence mechanisms described:

Gifts, communications, and medical representatives (visits, emails, WhatsApp)
Conflict of interest: representatives track prescribing targets and influence which drugs get prescribed
Media/press promotion: health articles and prime-time TV segments promoting drug narratives

Policy/regulatory concerns:

Some medications increasingly sold/provided without prescription (e.g., mentions omeprazole and analogues)
Medication advertising described as excessive and inappropriate

7) Cost and access: irrational pricing causes real harm

Limited access due to cost is presented as a severe public health issue.

Claims presented (Argentina):

About one-third of out-of-pocket spending is on medications
The poorest 20% stop acquiring medications 5 times more often than the richest

Effects:

Worsening disease progression
Patients presenting with more severe consequences due to delayed/insufficient treatment
Social/human harm from shortages and inability to obtain necessary medicines

8) Patient training and communication as a safety requirement

A major barrier is described as poor patient training/communication.

Anecdote: A woman couldn’t sleep for about three months due to a cough from enalapril, and she wasn’t warned; earlier adjustment could have been made with proper counseling.

Emphasis:

Healthcare teams must warn about adverse reactions and support adherence
In primary healthcare, adherence management for antihypertensives/antidiabetics/insulin is complex and requires support

9) Problems in prescribing practice and pharmaceutical marketing

Bad prescribing habits can include:

Choosing ineffective or unsafe medications
Increasing adverse reactions → worsening the condition or requiring hospitalization
Adding complications that increase costs

“Pharmaceutical marketing” is described as strategies that push certain drugs into the market.

10) Lack of evidence/experience with newer drugs and irrational combinations

The class raises concerns that some newer drugs enter markets with limited information:

Short-term safety studies
Insufficient post-marketing experience

Examples of irrational prescribing logic mentioned:

Fixed multi-component “flu” medications (antihistamine + antipyretic + analgesic) used without clear rationale
Drugs with addiction/toxicity or low safety margins
Large irrational price differences within the same therapeutic group

Price vs benefit example:

Esomeprazole vs omeprazole: esomeprazole is described as more expensive without added therapeutic advantage

11) “Diseases manufactured” / medicalization critique (as presented)

The class claims marketing can contribute to:

Expanding definitions/prevalence of conditions to increase treatment markets

Examples mentioned include:

Treating baldness with minoxidil
Managing menopause with medications (noting cancer risks and symptom issues)
Irritable bowel syndrome, restless legs syndrome
Labeling shy or less sociable people
Attention deficit disorder treatment (including adults)
Reframing sexual dysfunction categories (e.g., erectile dysfunction)
Big business example: sildenafil/Viagra
Osteoporosis described as heavily promoted

Methodology / instruction-style content

A) WHO-based principles: how to use rational medications (decision framework)

Step 1: Verify indication

Determine whether medication is truly needed vs prevention/lifestyle/non-drug options.

Step 2: Set correct regimen

Choose dosage appropriate to the patient.
Choose duration matching needs.

Step 3: Minimize number of drugs

Use the minimum necessary medication count.
Avoid unnecessary additions that increase interaction risk.

Step 4: Evaluate effectiveness first

Select based on clinical efficacy.

Step 5: Evaluate safety second

Select considering risk of adverse reactions and interactions.

Step 6: Consider convenience and practical usability

Ensure the regimen is feasible in the patient’s context.

Step 7: Consider cost (final but important)

Prefer more economical options when possible.
If the preferred option can’t be accessed, plan alternatives (“plan B”).

Step 8: Ensure ongoing supervision

Follow up to check:
- Response/effect (e.g., blood pressure outcomes)
- Adherence
- Need for adjustment (adding/changing drugs)

Step 9: Re-check the whole medication picture

Before adding a drug:
- Review what the patient already takes
- Check for interactions
- Confirm the new drug likely solves the problem rather than complicating it

Step 10: Include patient-centered education

Provide clear written and verbal instructions.
Explain possible adverse effects.
Confirm understanding (including language/cultural barriers).

B) WHO “Guide to Good Prescribing” (process described)

Prescribing is described as a reasonableness/rationalization process.

The prescriber:

Evaluates the patient in front of them
Selects medication considering:
- Risks vs benefits
- Costs and access feasibility
- Alternatives if access isn’t possible
Then:
- Defines the patient’s problem
- Sets specific treatment objectives
- Designs the therapeutic regimen to meet those objectives
- Ensures patient access with instructions

Crucially, the process continues with supervision/follow-up beyond the consultation:

Reassess response
Assess adherence
Refill and adjust if needed

C) “P-treatment” (personalized treatment) emphasis

Treatment should be patient-centered (“P-treatment”), tailored to the patient at that moment.

Includes consideration of:

Efficacy
Safety
Convenience
Cost (in an order prioritizing efficacy then safety)

Communication requirements:

Simple language instructions
Clear handwriting on prescriptions
Confirm patient understanding

Safety requirements:

Warn about adverse effects
Monitor and act on signs of adverse reactions

Behavioral/lifestyle component:

Assess and support relevant lifestyle habits (e.g., salt reduction for hypertension; contraindicated foods for diabetes)

D) WHO Essential Medicines concept (classification methodology mentioned)

The class references an essential medicines approach and categories:

V = “vital” (core, for prevalent pathologies; effective and suitable)
E = “essential” (important, though not necessarily the most critical)
N = “not necessary”

A reflective exercise is mentioned using Caladryl (topical anti-allergy medication) as an example of categorizing medicines.

E) Pharmacovigilance and team practice (operational guidance)

Pharmacovigilance is presented as a fundamental tool.

Future nurses/pharmacists should:

Act as managers of pharmacovigilance in their practice
Apply precautions in practical sessions (examples mentioned: vancomycin, aminoglycosides, penicillin)
Learn to recognize signs/symptoms of adverse reactions
Work in teams to improve medication-use studies for problematic practices

F) Practical access and context adjustments (patient-centered logistics)

Ensure medication usability given constraints:

Cold chain storage requirements
Electricity availability
Language barriers (use drawings; involve family members who translate if appropriate)
Whether the patient can realistically follow the plan

Cost is considered to prevent prescriptions from becoming harmful due to non-adherence caused by unaffordability.

G) Clinical guidelines and institutional lists

Clinical guidelines should:

Specify actions by context/stage
Support evidence-based decisions
Provide a standardized stepwise approach (drug A for stage A; switch only when circumstances arise)

Institutions should maintain updated:

Lists of essential medicines (described as updated annually by WHO)

People conducting these evaluations must be staffed/competent.

Conclusions implied by the class

Rational medication use requires clinical judgment + patient-centered practice + safety + cost/access consideration.
Irrational use is driven not only by clinical factors, but also by market forces, poor regulation, inadequate patient education, and biased promotion.
Solutions emphasized include training (undergraduate and ongoing) and tools such as WHO guidelines, essential medicines lists, pharmacovigilance, and good prescribing methods.

Speakers / sources featured (as named in the subtitles)

World Health Organization (WHO) — main source of frameworks and guidance (rational use, essential medicines list, guide to good prescribing, prescribing guidelines)
Nobel Prize winner in Medicine — quoted indirectly about a drug that “cures everything” not being profitable (exact name not provided)
Argentina pharmaceutical market / studies — referenced indirectly (market growth graph; studies on analgesic use; out-of-pocket medication spending and access)
Ben system / Ben classification — referenced as “vital/essential/not necessary” (origin not fully explained)
Ben system example medication names (not speakers): esomeprazole, omeprazole, aspirin, digoxin, insulin, enalapril, acetaminophen/paracetamol, omeprazole analogues, enalapril, vancomycin, aminoglycosides, penicillin, Caladryl, minoxidil, sildenafil/Viagra